JPRN-jRCT2080223253已完成3 期
A Phase 3, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 99
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Histologically confirmed diagnosis of primary non small lung cancer (NSCLC) on predominantly non-squamous histology.
- •2. MRI or CT scan of the brain must be done prior to surgery as it is considered standard of care.
- •3. Patients must be classified post-operatively as Stage IB, II or IIIA on the basis of pathologic criteria. In Japan, patients with Stage IB disease are not eligible.
- •4. Confirmation by the central laboratory that the tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M.
- •5. Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour.
- •6. Complete recovery from surgery and standard post-operative therapy (if applicable) at the time of randomization.
- •7. World Health Organization Performance Status of 0 to 1.
- •8. Female patients should be using adequate contraceptive measures, should not be breast feeding, and must have a negative pregnancy test prior to first dose of study drug; or female patients must have an evidence of non-child-bearing potential.
- •18 Years and older, Patients from Japan aged at least 20 years
排除标准
- •1. Treatment with any of the following:
- •- Pre-operative or post-operative or planned radiation therapy for the current lung cancer
- •- Pre-operative (neo-adjuvant) platinum based or other chemotherapy
- •- Any prior anticancer therapy
- •- Prior treatment with neoadjuvant or adjuvant EGFR-TKI at any time
- •- Major surgery (including primary tumour surgery, excluding placement of vascular access) within 4 weeks of the first dose of study drug
- •- Patients currently receiving medications or herbal supplements known to be potent inducers of cytochrome P450 (CYP) 3A4
- •- Treatment with an investigational drug within five half-lives of the compound or any of its related material.
- •2. Patients who have had only segmentectomies or wedge resections.
- •3. History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer, or other solid tumours curatively treated with no evidence of disease for > 5 years following the end of treatment.
- •4. Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy.
- •5. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).
- •6. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of AZD9291.
- •7. Any of the following cardiac criteria:
- •- Mean resting corrected QT interval (QTc) >470 msec, obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value.
- •- Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG.
- •- Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval.
- •8. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
- •9. Inadequate bone marrow reserve or organ function.
研究者
相似试验
招募中
1 期
A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).CTIS2023-506669-70-00Alexion Pharmaceuticals Inc.982
进行中（未招募）
1 期
Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCCResectable high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC)MedDRA version: 20.0 Level: PT Classification code 10041823 Term: Squamous cell carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001974-76-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.570
进行中（未招募）
1 期
Phase 3 Study of Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)Recurrent, Platinum-Sensitive Ovarian CancerMedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-005099-21-NOMersana Therapeutics, Inc.581
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to study the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents = 6 to <18 years of ageAcute Migraine (with or without aura)MedDRA version: 20.0Level: PTClassification code 10052787Term: Migraine without auraSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10027607Term: Migraine with auraSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: HLTClassification code 10027603Term: Migraine headachesSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-005246-15-PLPfizer Inc.640
进行中（未招募）
1 期
Combining chemotherapy with either the medication entospletinib or a placebo for adults with acute myeloid leukemia that has a nucleophosmin-1 abnormalityMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864Acute Myeloid LeukemiaEUCTR2021-000761-33-PLKronos Bio, Inc.180